# US 2010/0168203 A1 · Adenylyl cyclases as novel targets for antibactrial interventions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168203 A1
- Document ID: US20100168203A1
- Status: Published application
- Kind: A1
- Application number: 12/523,011
- Filed: 2008-01-11
- Published: 2010-07-01
- Earliest claimed: 2007-01-12
- Assignees: Cornell Research Foundation, Inc.
- Inventors: Lonny Levin; Jochen Buck; Leo Brizuela; Michael Pinnisi
- Web page: https://patentgrep.com/patent/US20100168203A1

## CPC

- A61K 31/415: 1,2-Diazoles
- A61P 31/04: Antibacterial agents
- G01N 2333/988: Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
- G01N 2500/00: Screening for compounds of potential therapeutic value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a method of preventing or treating a disease caused by bacterial infection by administering an effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of bacterial adenylyl cyclase that do not substantially modulate adenylyl cyclase of the subject. The invention also provides methods for culturing bacterial pathogens and methods for inducing the pathogenic state in vitro.

## Claims

### Claim 1

A method for the treatment of a subject with a disease caused by infection by bacteria, the method comprising: administering to a subject a therapeutic amount of a modulator of a bacterial adenylyl cyclase.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amount of modulator of bacterial adenylyl cyclase administered is effective at substantially preventing the bacteria from changing to a pathogenic state from a non-pathogenic state, or wherein the amount of the modulator of bacterial adenylyl cyclase administered causes the bacteria to substantially revert to a non-pathogenic state from a pathogenic state.

### Claim 3 (depends on 2)

The method of claim 2, wherein the modulator of the bacterial adenylyl cyclase substantially prevents the infecting bacteria from changing shape.

### Claim 4 (depends on 2)

The method of claim 2, wherein the modulator of the bacterial adenylyl cyclase substantially prevents the infecting bacteria from producing toxins.

### Claim 5 (depends on 2)

The method of claim 2, wherein the modulator of the bacterial adenylyl cyclase substantially prevents the infecting bacteria from germinating.

### Claim 6 (depends on 2)

The method of claim 2, wherein the modulator of the bacterial adenylyl cyclase substantially prevents the infecting bacteria from forming biofilms.

### Claim 7 (depends on 2)

The method of claim 2, wherein the modulator of the bacterial adenylyl cyclase substantially prevents the infecting bacteria from increasing or decreasing growth rate.

### Claim 8 (depends on 1)

The method of claim 1, wherein the modulator of the bacterial adenylyl cyclase inhibits the bacterial adenylyl cyclase.

### Claim 9 (depends on 1)

The method of claim 1, wherein the modulator of the bacterial adenylyl cyclase activates the bacterial adenylyl cyclase.

### Claim 10 (depends on 1)

The method of claim 1, wherein the modulator of the bacterial adenylyl cyclase has a substantially bactericidal effect upon the infecting bacteria.

### Claim 11 (depends on 1)

The method of claim 1, wherein the modulator of the bacterial adenylyl cyclase has a substantially bacteriostatic effect upon the infecting bacteria.

### Claim 12 (depends on 1)

The method of claim 1, wherein the amount of modulator of bacterial adenylyl cyclase administered does not inhibit or prevent growth of the bacteria.

### Claim 13 (depends on 1)

The method of claim 1, wherein the amount of modulator of bacterial adenylyl cyclase administered does not kill the bacteria.

### Claim 14 (depends on 1)

The method of claim 1, wherein the modulator of the bacterial adenylyl cyclase affects more than one bacterial adenylyl cyclase of one infecting bacteria.

### Claim 15 (depends on 1)

The method of claim 1, wherein the modulator of the bacterial adenylyl cyclase affects more than one bacterial adenylyl cyclase of more than one infecting bacteria.

### Claim 16 (depends on 1)

The method of claim 1, wherein the amount of modulator of bacterial adenylyl cyclase administered does not affect whether the bacteria enters a pathogenic state.

### Claim 17 (depends on 1)

The method of claim 1, wherein the bacterial adenylyl cyclase is CO2/HCO3/pH sensitive.

### Claim 18 (depends on 17)

The method of claim 17, wherein the modulator affects the response of the infecting bacterial adenylyl cyclase to CO2.

### Claim 19 (depends on 17)

The method of claim 17, wherein the modulator affects the response of the infecting bacterial adenylyl cyclase to HCO3.

### Claim 20 (depends on 17)

The method of claim 17, wherein the modulator affects the response of the infecting bacterial adenylyl cyclase to pH.

### Claim 21 (depends on 1)

The method of claim 1, wherein the bacterial adenylyl cyclase is selected from the group consisting of Class I, Class III, and Class IV adenylyl cyclase.

### Claim 22 (depends on 1)

The method of claim 1, wherein the infection is caused by bacteria selected from the group consisting of Gram negative bacteria, Gram negative cocci, Gram negative rods, Gram positive bacteria, Gram positive cocci, and Gram positive rods.

### Claim 23 (depends on 1)

The method of claim 1, wherein the infection by bacteria is caused by a spirochete.

### Claim 24 (depends on 1)

The method of claim 1, wherein the infection by bacteria is caused by enteric bacteria.

### Claim 25 (depends on 24)

The method of claim 24 wherein, the infection is caused by an enteric bacteria selected from the group consisting of Escherichia coli, Salmonella enterica, Shigella, Shigella dysenteriae, Vibrio cholerae, Vibrio vulnificus, Vibrio parahaemolyticus, Virio vulnificus, Campylobacter jejuni, Klebsiella, Enterobacter, Serratia, Proteus, Providencia, and Morganella.

### Claim 26 (depends on 1)

The method of claim 1 wherein, the infection is caused by a bacteria selected from the group consisting of Bacillus anthracis, Bacillus cereus, Clostridium tetani, Clostrium botulinum, Clostridium perfringens, Clostridium difficile, Mycobacterium tuberculosis Legionella pneumophilla, Vibrio cholera, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecalis, Streptococcus bovis, Streptococcus pneumoniae, Streptococcus viridans, Pseudomonas aeruginosa, Corynebacterium diphtheriae, Listeria monocytogenes, Burcella, Francisella tularensis, Yersinia enterocolitica, Yersinia pseudotuberculosis, Yersinia pestis, Pasteurella multocida, Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium avium, Mycobacterium leprae, Actinomyces israelii, Nocardia asteroides, Mycoplasma pneumoniae, Treponema pallidum, Borrelia brugdorferi, Borrelia afzelii, Borrelia garinii, Leptospira interrogans, Chlamydia psittaci, Chlamydia trachomatis, Chlamydia pneumoniae, Rickettsia rickettsii, Coxiella burnetii, R. Prowazekii, Gardnerella vaginalis, Lactobacillus, Peptococcus, Peptostreptococcus, Propionibacterium, Tropheryma, Burkholderia pseudomallei, and Burkholderia mallei.

### Claim 27 (depends on 1)

The method of claim 1, wherein the infection is caused by Pseudomonas aeruginosa.

### Claim 28 (depends on 1)

The method of claim 1, wherein the infection is caused by bacteria that are resistant to one or more antibacterial agents.

### Claim 29 (depends on 1)

The method of claim 1, wherein the subject is a eukaryote.

### Claim 30 (depends on 1)

The method of claim 1, wherein the subject is a plant.

### Claim 31 (depends on 1)

The method of claim 1, wherein the subject is an animal.

### Claim 32 (depends on 1)

The method of claim 1, wherein the subject is a bird.

### Claim 33 (depends on 32)

The method of claim 32, wherein the bird is poultry.

### Claim 34 (depends on 1)

The method of claim 1, wherein the subject is a fish.

### Claim 35 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 36 (depends on 35)

The method of claim 35, wherein the mammal is livestock or pet.

### Claim 37 (depends on 36)

The method of claim 36 wherein the livestock animal is selected form the group consisting of cattle, swine, and sheep.

### Claim 38 (depends on 36)

The method of claim 36 wherein the pet is selected form the group consisting of dogs, cats and horses.

### Claim 39 (depends on 35)

The method of claim 35, wherein the mammal is a human.

### Claim 40 (depends on 39)

The method of claim 39, wherein the human is immune compromised.

### Claim 41 (depends on 40)

The method of claim 40, wherein the immune compromised human is selected from the group consisting of a human infected with HIV, a human undergoing chemotherapy, a human affected by a blood cancer, a human transplant recipient, a human receiving immunosuppressant medication, a human receiving an opiod medication, and a human burn victim.

### Claim 42 (depends on 39)

The method of claim 39, wherein the human has an opportunistic lung infection.

### Claim 43 (depends on 42)

The method of claim 42, wherein the human is selected from the group consisting of a human who has asthma, a human who has cystic fibrosis, a human who has sarcoidosis.

### Claim 44 (depends on 39)

The method of claim 39, wherein the human has been exposed to airborne infectious agents.

### Claim 45 (depends on 44)

The method of claim 44, wherein the human is selected from the group consisting a human who has tuberculosis and a human with anthrax infection.

### Claim 46 (depends on 1)

The method of claim 1, wherein the modulator of bacterial adenylyl cyclase does not inhibit adenylyl cyclases of the subject.

### Claim 47 (depends on 1)

The method of claim 1, wherein the modulator of bacterial adenylyl cyclase is selective relative to adenylyl cyclases of the subject.

### Claim 48 (depends on 1)

The method of claim 1, wherein the modulator of bacterial adenylyl cyclase is sufficiently selective against adenylyl cyclases of the subject that a therapeutic effect upon the infecting bacteria can be achieved without toxic regulation of subject's adenylyl cyclase occurring.

### Claim 49 (depends on 1)

The method of claim 1, wherein the modulator of bacterial adenylyl cyclase is selected from the group consisting of small molecules, aptamers, and interfering RNA.

### Claim 50 (depends on 1)

The method of claim 1, wherein the modulator of bacterial adenylyl cyclase is selected from the group consisting of:
and combinations thereof.

### Claim 51 (depends on 1)

The method of claim 1, wherein the modulator of bacterial adenylyl cyclase is selected from catechol estrogens and derivatives thereof.

### Claim 52 (depends on 1)

The method of claim 1, further comprising administration of one or more additional therapeutic agents.

### Claim 53 (depends on 52)

The method of claim 52, wherein the additional therapeutic agent is an antibacterial agent.

### Claim at position 54

54-182. (canceled)
